Letters
Throughout the year, the AHA comments on a vast number of proposed and interim final rules put forth by the federal regulatory agencies. In addition, AHA communicates with federal legislators to convey the hospital field's position on potential legislative changes that would impact patients and patient care. Below are the most recent letters from the AHA to these bodies.
Latest
AHA letter to Representative Charles Dent endorsing HR 3537, the Synthetic Drug Control Act of 2015.
AHA strongly supports many of the provisions of the Health Benefit Plan Network Access and Adequacy Model Act (Model Act) as approved by the National Association of Insurance Commissioners' (NAIC)
AHA Expresses Concern Re: H.R. 3298, the Medicare Post-Acute Care Value-Based Purchasing Act of 2015
AHA letter to House Committee on Ways and Means Subcommittee on Health expressing concerns regarding H.R. 3298, the Medicare Post-Acute Care Value-Based Purchasing (PAC VBP) Act of 2015.
AHA comments on the America's Health Insurance Plans' (AHIP) testimony for the House Judiciary Subcommittee on Regulatory Reform, Commercial and Antitrust Law's September 10, 2015 hearing on "The Stat
Comment letter to the National Association of Insurance Commissioners' Subgroup regarding the Sept.